Clinical trial · Interventional
Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03
A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P03
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aimed to compare elective nodal irradiation versus involved field irradiation with or without concurrent chemotherapy and the addition of consolidation chemotherapy for patients with extensive lymphatic metastasis of esophageal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Involved Field Irradiation (IFI) | Other | — | UNRESOLVED |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
| Platinum-Based Drug | Drug | — | UNRESOLVED |
| SIB-IMRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- SIB-IMRT combined chemotherapy with IFI
- interventionNames
- Radiation: SIB-IMRT
- Drug: Paclitaxel
- Drug: Platinum-Based Drug
- Other: Involved Field Irradiation (IFI)
- type
- EXPERIMENTAL
- label
- SIB-IMRT with IFI
- interventionNames
- Radiation: SIB-IMRT
- Drug: Paclitaxel
- Drug: Platinum-Based Drug
- Other: Involved Field Irradiation (IFI)
Primary outcomes (3)
- measure
- Overall survival (OS)
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Inclusion Criteria: * Age\<70 * Diagnosis of clinical stage T2-4N0-1M1（According to UICC 2002） * A untreated squamous esophageal carcinoma * Karnofsky performance status(KPS)≥ 70 and Charlson score ≤3 * Adequate organ function * No known history of drug allergy * Blood routine examination : WBC≥4.0 * hepatic and renal function are normal Exclusion Criteria: * Age≥ 70 or ≤ 16 * Already received the treatment of chemotherapy or radiotherapy * Pregnant or lactating females * Known drug allergy * Without agreement of informed consent form * Insufficient hepatorenal function or Blood routine examination * Severe cardiovascular diseases, diabetes with uncontrolled blood sugar, mental disorders, uncontrolled severe infection, active ulceration which need intervention.
References
Publications (0)
Data not yet available